Trevi Therapeutics (NASDAQ:TRVI) Posts Earnings Results

Trevi Therapeutics (NASDAQ:TRVI) announced its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01, Zacks reports.

Trevi Therapeutics Stock Up 0.3 %

Trevi Therapeutics stock opened at $6.56 on Wednesday. The company has a market cap of $504.24 million, a PE ratio of -14.91 and a beta of 0.90. Trevi Therapeutics has a twelve month low of $2.30 and a twelve month high of $7.39. The company’s 50-day moving average price is $4.44 and its 200-day moving average price is $3.68.

Wall Street Analyst Weigh In

TRVI has been the topic of several analyst reports. D. Boral Capital reiterated a “buy” rating and set a $21.00 price target on shares of Trevi Therapeutics in a research note on Friday, March 7th. HC Wainwright lifted their price target on shares of Trevi Therapeutics from $7.50 to $12.50 and gave the stock a “buy” rating in a research note on Monday, March 10th. Raymond James upgraded shares of Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and lifted their target price for the company from $9.00 to $29.00 in a research note on Monday, March 10th. Oppenheimer lifted their target price on shares of Trevi Therapeutics from $12.00 to $20.00 and gave the company an “outperform” rating in a research note on Tuesday, March 11th. Finally, Needham & Company LLC lifted their target price on shares of Trevi Therapeutics from $8.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, March 10th. Seven research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Trevi Therapeutics has an average rating of “Buy” and a consensus target price of $15.94.

Insider Activity at Trevi Therapeutics

In related news, insider Farrell Simon sold 81,313 shares of the stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the completion of the sale, the insider now owns 76,900 shares of the company’s stock, valued at $519,075. This represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 24.37% of the stock is currently owned by insiders.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.